# Gilead Sciences, Inc. (GILD) — Q1-2016 Earnings Results

**Report date:** 2016-04-28 (after market close)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/GILD/earnings/Q1-2016

## Post-Earnings Brief

### Headline

Gilead Sciences Misses on EPS, Stock Down N/A%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $3.03 | N/A | -0.10% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management expressed a cautious optimism about future prospects. They noted the need for continued focus on innovation and market dynamics.

**Key quotes:**

> Management highlighted ongoing investments in research and development.

> They emphasized the importance of pipeline products for future growth.

### Guidance Changes

No guidance data was provided during the earnings call.

### What It Means

This earnings report indicates that Gilead Sciences is facing challenges in meeting earnings expectations, as reflected in the slight EPS miss. The lack of revenue data and guidance may lead to uncertainty among investors. The stock reaction is currently unavailable, but management's focus on future growth through R&D investments suggests they are looking to strengthen their position in the market.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/GILD/earnings/Q1-2016_